CD43 expression is associated with inferior survival in the non‐germinal centre B‐cell subgroup of diffuse large B‐cell lymphoma. (25th April 2013)

• Record Type: Journal Article
• Authors: Mitrovic, Zdravko; Iqbal, Javeed; Fu, Kai; Smith, Lynette M.; Bast, Martin; Greiner, Timothy C.; Aoun, Patricia; Armitage, James O.; Vose, Julie M.; Weisenburger, Dennis D.; Chan, Wing C.
• Is Part Of: British journal of haematology. Volume 162:Number 1(2013:Jul.)
• Page Start: 87
• Page End: 92
• Publication Date: 2013-04-25
• Subjects: Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1111/bjh.12356
• Languages: English
• ISSNs: 0007-1048

Abstract

<abstract abstract-type="main" xml:lang="en" id="bjh12356-abs-0001"> <title>Summary</title> <p>We evaluated the prognostic significance of CD43 (SPN), a membrane glycoprotein, in 140 patients with diffuse large B‐cell lymphoma (DLBCL) by tissue microarray (TMA) immunostaining, and gene expression profiling (GEP) in 43 patients. CD43 protein was expressed in 19% of the cases and was strongly related to the non‐germinal centre B‐cell (non‐GCB) subgroup by both TMA and GEP. Patients with CD43(+) DLBCL had an inferior 3‐year overall survival (OS) compared to those with CD43(‐) DLBCL (50% vs. 76%, <italic>P </italic>=<italic> </italic>0·01). Within the non‐GCB subgroup, patients with CD43(+) DLBCL had a particularly poor 3‐year OS (32% vs. 71%, <italic>P </italic>&lt;<italic> </italic>0·001). Gene set enrichment analysis within the activated B‐cell subgroup revealed significant enrichment in the stromal‐1 signature in CD43(−) cases. We conclude that CD43 is an adverse prognostic marker in DLBCL, and is preferentially expressed in the non‐GCB subgroup. The dismal outcome of CD43(+) cases in the non‐GCB subgroup may be explained, at least in part, by a less favourable microenvironment.</p> </abstract>